Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) had its target price decreased by RBC Capital Markets from $58.00 to $51.00 in a research report released on Wednesday. RBC Capital Markets currently has an outperform rating on the stock.

Several other brokerages also recently issued reports on TEVA. BTIG Research downgraded shares of Teva Pharmaceutical Industries from a buy rating to a neutral rating in a research note on Wednesday. Jefferies Group downgraded shares of Teva Pharmaceutical Industries from a buy rating to a hold rating and cut their target price for the company from $69.00 to $40.00 in a research note on Wednesday. Mizuho cut their target price on shares of Teva Pharmaceutical Industries from $45.00 to $40.00 and set a neutral rating on the stock in a research note on Wednesday. Morgan Stanley downgraded shares of Teva Pharmaceutical Industries from an overweight rating to an equal weight rating and cut their target price for the company from $63.00 to $42.00 in a research note on Wednesday. Finally, Royal Bank Of Canada dropped their price target on shares of Teva Pharmaceutical Industries from $71.00 to $58.00 and set an outperform rating on the stock in a research note on Monday. Thirteen investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Teva Pharmaceutical Industries currently has an average rating of Buy and a consensus target price of $60.00.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) traded up 3.26% during trading on Wednesday, reaching $39.31. The company had a trading volume of 4,680,456 shares. The firm has a market capitalization of $35.93 billion, a P/E ratio of 26.26 and a beta of 0.73. Teva Pharmaceutical Industries has a 52-week low of $37.25 and a 52-week high of $66.55. The company has a 50-day moving average of $42.97 and a 200-day moving average of $49.87.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, November 15th. The company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.29 by $0.02. The firm earned $5.56 billion during the quarter, compared to the consensus estimate of $5.71 billion. Teva Pharmaceutical Industries had a return on equity of 17.77% and a net margin of 7.56%. The firm’s revenue for the quarter was up 15.3% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.35 earnings per share. Analysts expect that Teva Pharmaceutical Industries will post $5.16 EPS for the current fiscal year.

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 20th. Stockholders of record on Monday, December 5th will be given a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.57%. Teva Pharmaceutical Industries’s dividend payout ratio is 58.39%.

A number of large investors have recently bought and sold shares of TEVA. Krilogy Financial LLC boosted its stake in Teva Pharmaceutical Industries by 1.0% in the second quarter. Krilogy Financial LLC now owns 2,635 shares of the company’s stock valued at $132,000 after buying an additional 25 shares in the last quarter. Veritable L.P. raised its stake in shares of Teva Pharmaceutical Industries by 0.5% in the second quarter. Veritable L.P. now owns 5,216 shares of the company’s stock valued at $262,000 after buying an additional 26 shares during the last quarter. Toronto Dominion Bank raised its stake in shares of Teva Pharmaceutical Industries by 0.6% in the second quarter. Toronto Dominion Bank now owns 6,025 shares of the company’s stock valued at $304,000 after buying an additional 35 shares during the last quarter. Trust Co raised its stake in shares of Teva Pharmaceutical Industries by 0.3% in the first quarter. Trust Co now owns 13,980 shares of the company’s stock valued at $748,000 after buying an additional 40 shares during the last quarter. Finally, Cribstone Capital Management LLC raised its stake in shares of Teva Pharmaceutical Industries by 1.3% in the third quarter. Cribstone Capital Management LLC now owns 3,241 shares of the company’s stock valued at $144,000 after buying an additional 41 shares during the last quarter. 63.00% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Receive News & Stock Ratings for Teva Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd. and related stocks with our FREE daily email newsletter.